attach research report excerpt
research report written
entir broker partner auerbach
grayson auerbach grayson
auerbach grayson distributing/provid
research report consider
maintain hold rate increas price target per share
examin opportun respiratori solut copd chronic obstruct
pulmonari diseas next logic market connect care strategi
approach indic non-invas ventil devic
cater severely-il end copd spectrum reimburs pathway
still evolv copd usa connect care becom import
value-bas payment evolv benefit seen manag chronic
stabl copd may need engag modal nasal high
flow properli monetis copd
non-invas ventil niv use hospit set copd
although begin phase nasal highflow similarli efficaci
much toler form respiratori support clinic success studi
shown posit benefit niv use homecar set reduc
exacerb reduc hospit readmiss concret efficaci data limit
sever patient on-going trial close evid gap encourag
reimburs increas adopt
success built cloud-bas platform improv patient complianc
osa obstruct sleep apnea therapi well improv physician
engag think pursu strategi copd patient
typic non- compliant histor improv patient engag tool
across rang diseas shown improv complianc therefor
outcom approach allow leverag technolog broader patient
group could result higher-margin product growth
non-invas ventil amen sever patient cohort patient
typic closer die damag done lung
irrevers key implic chang think
first annuiti gener sell consum reduc sinc patient
like die near mid-term second margin clinic benefit
connect care approach bring patient limit sinc diseas
caus irrevers damag third may need engag nasal
highflow market order keep market trend
hold connect care copd deep dive
maintain hold rate increas price target per
share examin opportun respiratori solut copd
chronic obstruct pulmonari diseas next logic market
approach
indic non-invas ventil devic cater
severely-il end copd spectrum reimburs pathway still
evolv copd usa connect care becom
import value-bas payment evolv benefit
seen manag chronic stabl copd may need engag
modal nasal high flow properli monetis copd
niv viabl treatment option copd non-invas ventil niv
use hospit set copd although begin
phase nasal highflow similarli efficaci much toler
form respiratori support clinic success studi shown
posit benefit niv use homecar set reduc exacerb
reduc hospit readmiss concret efficaci data limit sever
patient on-going trial close evid gap encourag
reimburs increas adopt
connect care patient engag tool copd could mimic
success sleep success built cloud-bas
platform improv patient complianc osa obstruct sleep
apnea therapi well improv physician engag think resm
pursu strategi copd patient typic non-
compliant histor improv patient engag tool across rang
diseas shown improv complianc therefor outcom
approach allow leverag technolog broader patient group
could result higher-margin product growth
current niv popul group sick save
non-invas ventil amen sever patient cohort
patient typic closer die damag done
lung irrevers key implic
chang think first annuiti gener sell consum
reduc sinc patient like die near mid-term second
margin clinic benefit connect care approach bring
patient limit sinc diseas caus irrevers damag third
may need engag nasal highflow market order keep
market trend
pp risk catalyst
share issu
issu wilson advisori stockbrok limit abn australian financi servic licenc particip asx group
read conjunct disclosur disclaim report import disclosur regard compani subject report explan
recommend found end document
health equip suppli
profit loss
fund equiti
fund debt
fund cash
health equip suppli
recent host kol call lead us pulmonologist valu use
non-invas ventil niv homecar set note signific challeng
reimburs hinder use niv home fact reimburs issu
would prescrib niv patient present hospit copd
chronic obstruct pulmonari diseas exacerb although hospit
incentivis fine medicar impos hospit whose patient readmit within
day consult note fine outweigh hospit profit
hospit system us financi motiv reduc number
patient exacerb readmit hospit note payor
would need see clinic data chang differ geographi
name european countri well australia/nz robust homecar
reimburs offer valu base medicin becom popular approach
reimburs clinic adopt homecar respiratori solut improv
estim copd homecar revenu less resm us busi right
equal nascent fph slightli differ patient popul target
nasal highflow niv devic evid develop earli encourag health
econom benefit resm pursu patient cohort requir niv via
vpap hardwar associ consum although expens astral
could also use howev see copd growth challeng vpap
machin astral prescrib copd patient niv solut
amen late stage patient annuiti gener consum may
short-liv fulfil connect care/pati engag strategi copd resm
may need invest hardwar consum use earlier diseas
cours redm like need engag nasal highflow market either
develop market high flow nasal cannula acquir smaller
moder establish compani nasal highflow space competitor fisher paykel
healthcar fph cover buy target price click recent publish
figur resm vpap machin quattro nv full face mask
data around efficaci niv mix although gener consensu
niv devic work field wait evid prove
fact meaning clinic health econom benefit two pulmonologist
consult thought hot-hmv provid meaning insight treat sever
copd patient paper motiv materi chang broader practic view
data convinc least specif subgroup patient hot-hmv trial
conduct critic valid import homecar copd outcom
health equip suppli
remind copd chronic obstruct pulmonari diseas chronic progress
diseas caus airflow obstruct involv two relat diseas chronic
bronchiti irrevers inflamm mucou membran emphysema
destruct lung tissu peopl world-wide diagnos diseas
meaning number patient diseas diagnos copd larg
market addit respiratori devic servic improv clinic outcom
qualiti life copd patient homecar set current cure
copd current pharmacolog treatment work reliev symptom reduc
exacerb hospit although remain unmet medic need even
patient current treat
well-establish respiratori therapi homecar set reduc
likelihood exacerb lead hospit readmiss especi import sinc
hospit penal patient re-admit especi valuabl later
stage copd patient rate gold gold scale diseas sever one
treatment option copd patient especi sever one use non-invas
ventil addit oxygen therapi home set small uncontrol
studi shown efficaci niv copd patient led increas
uptak howev need larger random studi
clinic benefit niv
hot hmv trial conduct uk enrol patient evalu use
home non-invas ventil home oxygen therapi copd patient persist
hypercapnia follow acut life-threaten copd exacerb requir acut
non-invas ventil primari endpoint time readmiss death within
month median time readmiss death month hot home oxygen
therapi hnv home non-invas ventil group vs month hot alon
cohort readmiss within month risk hot hnv group vs
hot group repres absolut risk reduct data support
hypercapn patient follow life-threaten copd exacerb benefit non-
invas ventil homecar set justifi niv sever group
patient although use outsid nich patient cohort would requir data
sjode mw cook cr readmiss penalti chronic obstruct pulmonari diseas stress hospit care vulner patient
popul american journal respiratori critic medicin
murphi pb rehal arban et al effect non-invasive ventil oxygen therapi vs oxygen therapi alon hospit readmiss death
acut copd exacerb random clinic trial jama
health equip suppli
figur reduc risk rehospit death hot-hmv trial
murphi pb rehal arban et al effect non-invasive ventil oxygen therapi vs oxygen
therapi alon hospit readmiss death acut copd exacerb random clinic
rescu respiratori support copd acut exacerb struick
enrol broader copd patient popul fail detect differ outcom
patient treat niv studi evalu
patient copd alloc niv group alloc
standard treatment group one year discharg niv patient
standard treatment patient readmit hospit die mean number
day event day niv group day standard care group
year readmiss hospit respiratori caus occur niv patient vs
standard care patient also mortal benefit patient niv
group die within year vs niv group differ annual mean
number exacerb howev studi show hypercapnia improv
significantli niv group standard care group qualiti life
significantli improv niv
health equip suppli
connect care approach copd improv
provid rang physician dme home medic equip provid
caregiv must implement new effect solut connect patient hospit
home develop effect respons care plan data tool real-tim
monitor platform allow care provid improv copd care throughout clinic care
pathway hospit home implement treatment strategi prevent
exacerb industri move toward value-bas model connect care
methodolog allow patient take control treatment improv
complianc ensur receiv optim treatment condit
given point time improv patient outcom associ health
econom improv gener healthcar system
us telemedicin reimburs although countri
associ superior outcom patient engag tool
includ sleep platform also proven improv complianc treatment
therefor outcom concern value-disconnect approach late
stage copd patient howev sinc patient close death even
complianc treatment stage unlik improv surviv meaning
margin think technolog best appli earlier stage patient
opportun slow diseas progress
figur show three area target improv care qualiti patient
complianc copd set
figur approach improv patient outcom via connect care
ogunbayo oj russel newham jj et al understand factor affect self-manag copd
perspect healthcar practition qualit studi npj primari respiratori medicin
health equip suppli
use telemedicin especi combin activ patient engag measur
result clinic improv patient across multipl studi although studi
necessarili align directli rmd technolog think illustr
exampl prove patient engag increas physician engag
posit effect patient outcom reduc healthcar expenditur copd
promet studi assess patient sever copd month period
patient receiv convent care cc home telemedicin ht ht cohort
decreas number emerg room visit vs cc group reduc number
hospit ht vs cc reduc length stay ht day vs day
cc group reduc need niv patient vs cc cohort averag
day first exacerb day cc group vs day ht group
closecar harrow ccg commiss merck healthcar servic divis trial patient
monitor servic call closercar provid patient remot monitor devic
wirelessli link nurs nurs call patient see abnorm result
monitor close contact local commun health team three
month use servic patient experienc drop hospit admiss
drop visit reduct night stay hospit cost save
patient previous admit hospit
east north hartfordshir ccg project medtron devic use remot
monitor vital sign copd patient agre protocol patient across train
urgent care nurs result reduct gp appoint patient
satisfact complianc rate treatment
safemobil care use valu relat blood pressur weight record
commun app result less nurs phone contact fewer
nurs visit reduct overal contact reduct call
gp reduct visit gp reduc number unplan copd
homepod homepod studi patient patient copd sent home
touch screen tablet pair medic devic blood pressur monitor puls oximet
weigh scale data transmit real time clinician servic began
result save compar usual care reduct gp
appoint reduct emerg admiss hospit reduct
local hour call medic adher also improv follow patient
awar direct impact complianc underli
prescrib uk nh app allow copd patient use finger
probe measur heart rate blood oxygen level everi day enter
app app learn individu normal rang within month alert
physician measur fall outsid normal rang month trial
reduc hospit admiss gp visit show remot monitor
abil reduc overal healthcar cost patient contact
respiron studi evalu reduc hospit use home niv copd
respiron conduct studi use advanc niv modal trilog titrat
maintain airway patenc target tidal volum use associ reduc
rehospit rate studi evalu payer perspect patient outcom
year period look annual number admiss surviv patient
health equip suppli
hospit base case defin patient sever copd evalu
cumul save day hospit cover
patient sever copd assum patient sever copd cumul save
associ homecar day result reduct
admiss day period cumul save day
payer perspect defin pt copd scenario examin save
payer pt sever copd advanc niv
associ year admiss year hospit admiss compar
year admiss year admiss patient receiv niv
homecar
patient connect reduc complianc chest physician
pulmonologist current prescrib long term oxygen therapi bulk copd
patient ltot long term oxygen therapi patient frequent use oxygen less
prescrib time overestim complianc one paper show
patient receiv oxygen therapi receiv instruct oxygen use
know oxygen prescript connect care approach provid patient
educ monitor support cost effect addit inpati
even outpati visit could help allevi frequent cite reason patient
adher
need valid niv copd homecar
real-lif efficaci health econom studi
improv select process better identifi specif patient group benefit
homecar program
payor would requir sleep studi blood ga factor suggest
patient would benefit niv homecar set
increas price target base modest npat ep
uplift account modest increas copd homecar sale
price target base dcf methodolog current valuat multipl
attribut premium stock versu intern med-tech peer
ev/ebitda basi premium recogn market leadership superior earn qualiti
potenti growth option indic sleep via connect care strategi
risk catalyst
margin aud eur exposur patent infring suit
catalyst underli diagnosi rate acquisit new mask product cycl
gross margin improv option heart failur copd chronic diseas
health equip suppli
resm inc develop manufactur sell posit air pressur pap devic treatment sleep disord breath recent
year compani diversifi pap offer market oral applianc ventil form respiratori support
report solid result revenu ep come estim consensu beat driven
unexpect boost japan respond favour reimburs chang outsid row sale line us perform
miss sale estim airsens product cycl matur growth may revert industri pace see platform
refresh lift ep forecast maintain hold rate revis price target per cdi per share us
intang goodwil
grow easier access diagnosi sleep disord
net debt averag
rel short product cycl refresh price point
new devic area
gross margin expos fx aud sgd vs usd
 sg typic net sale
product mix higher-end apap ventil bilevel mask
higher gross margin
competit intensifi low-end cpap market
restor sustain industri us devic volum flow
increment margin benefit mix shift apap
risk view
increas competit price point
slower-than-expect market growth particularli challeng
price reimburs challeng usa elsewher
relat poor complianc cpap
health equip suppli
disclaim disclosur
